Table 2 The genotype distributions of MDM2 SNP309 in the cases with gastric carcinoma and healthy controls
|  | Controls (n = 574) | Patients (n = 574) | Crude OR (95% CI) | Pvalue | Adjusted OR (95% CI)†| Pvalue |
|---|---|---|---|---|---|---|
Genotype | Â | Â | Â | Â | Â | Â |
  T/T | 34.7% | 30.1% | 1.00 |  |  |  |
  T/G | 51.6% | 45.3% | 1.01 (0.78-1.32) | 0.94 | 1.01 (0.78-1.31) | 0.95 |
  G/G | 13.7% | 24.6% | 2.05 (1.46-2.89) | < 0.01 | 2.06 (1.46-2.90) | < 0.01 |
Recessive model | Â | Â | Â | Â | Â | Â |
  T carriers | 86.3% | 75.4% | 1.00 |  |  |  |
  G/G | 13.7% | 24.6% | 2.04 (1.51-2.77) | < 0.01 | 2.05 (1.51-2.78) | < 0.01 |
Dominant model | Â | Â | Â | Â | Â | Â |
  T/T | 31.2% | 30.1% | 1.00 |  |  |  |
  G carriers | 68.8% | 69.9% | 1.23 (0.96-1.58) | 0.10 | 1.23 (0.96-1.58) | 0.10 |